Nimodipine improves information processing in substance abusers.
We examined whether nimodipine can improve information processing in healthy drug abusers using cognitive event-related potential (ERP) methodology. Placebo and 30- and 60-mg doses of nimodipine were administered on separate days in a random double-blind design to twelve male subjects, who used cocaine and/or opiates as well as alcohol and marijuana. The subjects performed the auditory rare event monitoring (AREM) task and the paired letter version of the visual continuous performance task (CPT) before oral drug administration as well as one and two hours after drug ingestion. The EEG was recorded from 7 scalp locations. The P3 component of the ERPs to the target stimulus was reduced with repeated testing on the placebo day. The 30-mg dose of nimodipine blocked the decrease in P3, which reflects stimulus evaluation in both tasks. Chronic administration of nimodipine may alleviate the cognitive deficits observed in substance abusers during abstinence and prevent treatment relapse.
D000328:Adult; D000437:Alcoholism / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D000704:Analysis of Variance; D003042:Cocaine; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects; D005071:Evoked Potentials / Q000187:drug effects; D006556:Heroin Dependence / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009553:Nimodipine / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology*
D018696:Neuroprotective Agents; D009553:Nimodipine; D003042:Cocaine